Andere Kunden interessierten sich auch für
![Exploring the Adoption of Implantable Brain Stimulation Into Standard of Care for Central Nervous System Disorders]( "Exploring the Adoption of Implantable Brain Stimulation Into Standard of Care for Central Nervous System Disorders")
Exploring the Adoption of Implantable Brain Stimulation Into Standard of Care for Central Nervous System Disorders25,99 €![Non-Invasive Neuromodulation of the Central Nervous System]( "Non-Invasive Neuromodulation of the Central Nervous System")
Non-Invasive Neuromodulation of the Central Nervous System47,99 €![Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders]( "Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders")
Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders50,99 €![Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors]( "Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors")
Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors66,99 €![Enabling Novel Treatments for Nervous System Disorders by Improving Methods for Traversing the Blood-Brain Barrier]( "Enabling Novel Treatments for Nervous System Disorders by Improving Methods for Traversing the Blood-Brain Barrier")
Enabling Novel Treatments for Nervous System Disorders by Improving Methods for Traversing the Blood-Brain Barrier62,99 €![Biomarker Tests for Molecularly Targeted Therapies]( "Biomarker Tests for Molecularly Targeted Therapies")
Biomarker Tests for Molecularly Targeted Therapies68,99 €![Advancing Therapeutic Development for Pain and Opioid Use Disorders Through Public-Private Partnerships]( "Advancing Therapeutic Development for Pain and Opioid Use Disorders Through Public-Private Partnerships")
Advancing Therapeutic Development for Pain and Opioid Use Disorders Through Public-Private Partnerships49,99 €
"On April 23 and 24, 2019 the Forum on Neuroscience and Nervous System Disorders convened a workshop titled "Advancing Gene-Targeted Therapies for Central Nervous System Disorders" in Washington, DC. This public workshop brought together experts and key stakeholders from academia, government, industry, philanthropic foundations, and disease/patient-focused nonprofit organizations to explore approaches for advancing the development of gene-targeted therapies for central nervous system (CNS) disorders, and implications of developing these therapies. Participants explored lessons learned from both successful and unsuccessful clinical development programs; new knowledge about the genetic underpinnings of brain disorders; the current status and future potential of gene-targeted therapies for CNS disorders; challenges and potential solutions for translating preclinical findings to approved therapies; and patient and caregiver perspectives. They also discussed what will be needed to develop these therapies for common disorders such as Alzheimer's and Parkinson's disease, as well as neuropsychiatric and neurodevelopmental disorders such as schizophrenia and autism. The workshop included approaches that target both DNA and RNA, as well as gene products using viral vectors, antisense oligonucleotides, and RNA interference. This publication summarizes the presentations and discussion of the workshop"--Publisher's description
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.